Certara Inc header image

Certara Inc

CERT

Equity

ISIN null / Valor 58446660

NASDAQ (2026-04-24)
USD 6.32+5.33%

Certara Inc
UMushroom community rating:

star star star star star
1.00 1 votes No rating yet
NegativeNeutralPositive

About company

Certara Inc is a leading provider of drug-development consultation services, leveraging the expertise of over 650 healthcare and pharmaceutical professionals along with cutting-edge technological solutions to accelerate regulatory and commercial success for their clients. With a track record of over 7,000 customer projects spanning various practice areas and drug development phases, Certara has established itself as a trusted partner in the industry. Additionally, their platform, utilized by over 6,000 discovery scientists, offers self-service data access and integrated analysis solutions for small molecule and biologics research.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (15.04.2026):

Certara Inc — fourth quarter and full fiscal year 2025: full-year revenue of $418.8M (up 9%) and adjusted EBITDA of $134.5M (up 10%); fourth‑quarter revenue of $103.6M (up 3%) and adjusted EBITDA of $32.5M (down 3%). Management forecasts 2026 revenue growth of 0–4%, an adjusted EBITDA margin of 30–32% and adjusted diluted EPS of $0.44–$0.48.

Quarter and Year Revenue

Q4 2025 revenue: $103.6M (+3% year‑over‑year; +2% constant currency). FY2025 revenue: $418.8M (+9% reported; +8% constant currency).

Profitability and Adjusted Metrics

Q4 2025 adjusted EBITDA: $32.5M (down 3% vs. Q4 2024). FY2025 adjusted EBITDA: $134.5M (up 10% vs. FY2024). FY2025 adjusted diluted EPS: $0.44 (FY adjusted net income $70.9M).

GAAP Results

Q4 2025 GAAP net loss: $5.9M (versus net income $6.6M in Q4 2024); Q4 diluted EPS $(0.04). FY2025 GAAP net loss attributable to common stockholders: $(1.6)M; FY diluted EPS $(0.01).

Software vs. Services

Q4 software revenue: $46.4M (+10% reported, +8% CC). Q4 services revenue: $57.3M (‑1% reported, ‑2% CC). For FY2025, software $183.3M (+18% reported) and services $235.6M (+3%).

Bookings and Demand Signals

Q4 total bookings: $155.2M (+7% YoY). Q4 software bookings: $56.1M (‑6% YoY); Q4 services bookings: $99.1M (+17% YoY), indicating stronger services contract momentum despite software bookings pressure.

Balance Sheet & Cash Flow Highlights

Cash and cash equivalents at 12/31/2025: $189.4M (up from $179.2M). Net cash provided by operations for FY2025: $96.3M. Long‑term debt (net of current portion): ~$290.1M. Company repurchased $42.6M of stock in FY2025.

Guidance & Management Notes for 2026

Full‑year 2026 outlook: revenue growth 0–4%, adjusted EBITDA margin ~30–32%, adjusted diluted EPS $0.44–$0.48, and fully diluted shares 160–162M. New CEO Jon Resnick (effective Jan 1, 2026) plans strategic sharpening, increased R&D and commercial execution improvements through 2026.

Summarized from source with an LLMView Source

Key figures

-56.2%1Y
-74.0%3Y
-79.7%5Y

Performance

61.4%1Y
51.1%3Y
54.4%5Y

Volatility

Market cap

1006 M

Market cap (USD)

Daily traded volume (Shares)

3,296,884

Daily traded volume (Shares)

1 day high/low

10.64 / 10.33

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

1.00

1 votes
Performance:
starstarstarstarstar
2.00
Innovation:
starstarstarstarstar
2.00
Society:
starstarstarstarstar
1.00
Nature:
starstarstarstarstar
1.00
Pius Wolbert
Switzerland, 16 Oct 2025
star star star star star
/

EQUITIES OF THE SAME SECTOR

Netflix Inc
Netflix Inc Netflix Inc Valor: 1413346
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.41%USD 92.44
NVIDIA Corp
NVIDIA Corp NVIDIA Corp Valor: 994529
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%USD 208.27
Advanced Micro Devices Inc
Advanced Micro Devices Inc Advanced Micro Devices Inc Valor: 903491
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
13.91%USD 347.81
Alphabet Inc
Alphabet Inc Alphabet Inc Valor: 29798545
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.35%USD 342.32
SK hynix Inc
SK hynix Inc SK hynix Inc Valor: 18382960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.38%EUR 744.00
Brady Corp
Brady Corp Brady Corp Valor: 913942
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.69%USD 80.70
CDW Corporation
CDW Corporation CDW Corporation Valor: 21034308
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.84%USD 135.32
Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc Biomarin Pharmaceutical Inc Valor: 729021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.48%USD 53.18
Kura Oncology Inc
Kura Oncology Inc Kura Oncology Inc Valor: 28160920
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.11%USD 9.26
Array Technologies Inc
Array Technologies Inc Array Technologies Inc Valor: 57373259
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 8.11